Home > Boards > US Listed > Medical - Drugs > MyMD Pharmaceuticals Inc (MYMD)

Johns Hopkins Medicine Researchers to Present Data on

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
BioFan1 Member Profile
 
Followed By 0
Posts 3
Boards Moderated 0
Alias Born 01/26/21
160x600 placeholder
MyMD Pharmaceuticals Set to Join Russell Microcap® Index Business Wire - 6/7/2021 10:02:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/18/2021 6:11:59 AM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) Edgar (US Regulatory) - 5/18/2021 6:07:21 AM
MyMD Pharmaceuticals Appoints David Rini, Professor at the Johns Hopkins School of Medicine, to Scientific Advisory Board Business Wire - 5/17/2021 9:00:00 AM
MyMD Pharmaceuticals Schedules Business Update Conference Call Business Wire - 5/12/2021 9:00:00 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 5/12/2021 6:05:34 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 5/11/2021 4:28:20 PM
Securities Registration Statement (simplified Form) (s-3/a) Edgar (US Regulatory) - 4/28/2021 5:26:41 PM
Johns Hopkins Medicine Researchers to Present Data on MyMD Pharmaceuticals’ Supera-CBD at the 3rd Annual Neuroimmunology Dr... Business Wire - 4/28/2021 10:13:00 AM
Statement of Beneficial Ownership (sc 13d) Edgar (US Regulatory) - 4/27/2021 6:02:14 AM
MyMD Pharmaceuticals Announces Issuance of Allowance from United States Patent & Trademark Office for Synthetic Cannabinoid C... Business Wire - 4/22/2021 9:20:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/22/2021 6:04:24 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/21/2021 5:55:31 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/21/2021 4:55:52 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/21/2021 4:54:18 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 4/21/2021 4:49:54 PM
MyMD Pharmaceuticals Begins Trading on Nasdaq Business Wire - 4/19/2021 9:00:00 AM
BioFan1   Wednesday, 04/28/21 01:16:02 PM
Re: None
Post # of 83 
Johns Hopkins Medicine Researchers to Present Data on MyMD Pharmaceuticals’ Supera-CBD at the 3rd Annual Neuroimmunology Drug Development Summit
BUSINESS WIRE 10:13 AM ET 4/28/2021

BALTIMORE--(BUSINESS WIRE)-- MyMD Pharmaceuticals, Inc.(MYMD) , a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, announced today that researchers from the Johns Hopkins University School of Medicine will present the results of new research on the company’s compound Supera-CBD at the 3rd Annual Neuroimmunology Drug Development Summit. The poster presentation will discuss the preclinical cannabidiol (CBD) derivative that targets endogenous cannabinoid receptor type 2 for the treatment of psychiatric disorders. The researchers studied the compound in depression and anxiety-related phenotypes in mice.

“This presentation of preclinical research will highlight the potential of Supera-CBD to address unmet needs in psychiatry," said Adam Kaplin, M.D., Ph.D., Chief Scientific Officer of MyMD Pharmaceuticals(MYMD).

Researchers Chantelle Terrillion, Ph.D., Instructor in Neuroscience, and Anupama Kumar, MBBS, Research Associate in Psychiatry and primary investigator on the study, will present findings from preclinical studies on the role of Supera-CBD. Early findings revealed Supera-CBD’s potent anxiolytic properties. The data being presented at the conference also demonstrate that Supera-CBD binds to CB2 with almost four-times the affinity of CBD. Other research has shown that binding to CB2 potentially mediates a number of the therapeutic effects of CBD, including its anxiolytic, antinociceptive, anticonvulsant, antipsychotic, neuroprotective and anti-inflammatory effects.

Details of the poster presentation are as follows:

Title: Supera-CBD: A Novel CBD Derived Drug Candidate

Abstract Number: 1858

Date and Time: April 28, 2021 at 4:15 p.m. ET.

Access to Poster: The poster will be available at the conference website’s media library as well as on MyMD.com/pipeline/supera-cbdafter the time noted above.


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences